Literature DB >> 20133890

Criteria for scientific evaluation of novel markers: a perspective.

Karel G M Moons1.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20133890     DOI: 10.1373/clinchem.2009.134155

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  21 in total

1.  Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules.

Authors:  Chad V Pecot; Ming Li; Xueqiong J Zhang; Rama Rajanbabu; Ciara Calitri; Aaron Bungum; James R Jett; Joe B Putnam; Carol Callaway-Lane; Steve Deppen; Eric L Grogan; David P Carbone; John A Worrell; Karel G M Moons; Yu Shyr; Pierre P Massion
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-28       Impact factor: 4.254

Review 2.  Biomarkers of risk to develop lung cancer in the new screening era.

Authors:  Thomas Atwater; Pierre P Massion
Journal:  Ann Transl Med       Date:  2016-04

3.  Extubation outcome after a successful spontaneous breathing trial: A multicenter validation of a 3-factor prediction model.

Authors:  Yang Liu; Y U Mu; Guo-Qiang Li; Xin Yu; Pei-Jun Li; Zhi-Qi Shen; Hao-Xun Wang; Lu-Qing Wei
Journal:  Exp Ther Med       Date:  2015-08-12       Impact factor: 2.447

Review 4.  Advances in proteomic strategies toward the early detection of lung cancer.

Authors:  Mohamed Hassanein; Jamshedur S M Rahman; Pierre Chaurand; Pierre P Massion
Journal:  Proc Am Thorac Soc       Date:  2011-05

5.  Incorporating published univariable associations in diagnostic and prognostic modeling.

Authors:  Thomas P A Debray; Hendrik Koffijberg; Difei Lu; Yvonne Vergouwe; Ewout W Steyerberg; Karel G M Moons
Journal:  BMC Med Res Methodol       Date:  2012-08-10       Impact factor: 4.615

6.  Liver function tests and risk prediction of incident type 2 diabetes: evaluation in two independent cohorts.

Authors:  Ali Abbasi; Stephan J L Bakker; Eva Corpeleijn; Daphne L van der A; Ron T Gansevoort; Rijk O B Gans; Linda M Peelen; Yvonne T van der Schouw; Ronald P Stolk; Gerjan Navis; Annemieke M W Spijkerman; Joline W J Beulens
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

Review 7.  Prognosis Research Strategy (PROGRESS) 2: prognostic factor research.

Authors:  Richard D Riley; Jill A Hayden; Ewout W Steyerberg; Karel G M Moons; Keith Abrams; Panayiotis A Kyzas; Núria Malats; Andrew Briggs; Sara Schroter; Douglas G Altman; Harry Hemingway
Journal:  PLoS Med       Date:  2013-02-05       Impact factor: 11.069

Review 8.  Prognosis Research Strategy (PROGRESS) 3: prognostic model research.

Authors:  Ewout W Steyerberg; Karel G M Moons; Danielle A van der Windt; Jill A Hayden; Pablo Perel; Sara Schroter; Richard D Riley; Harry Hemingway; Douglas G Altman
Journal:  PLoS Med       Date:  2013-02-05       Impact factor: 11.069

9.  Prognosis research strategy (PROGRESS) 4: stratified medicine research.

Authors:  Aroon D Hingorani; Daniëlle A van der Windt; Richard D Riley; Keith Abrams; Karel G M Moons; Ewout W Steyerberg; Sara Schroter; Willi Sauerbrei; Douglas G Altman; Harry Hemingway
Journal:  BMJ       Date:  2013-02-05

10.  Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. the CoLaus study.

Authors:  Pedro Marques-Vidal; Rémy Schmid; Murielle Bochud; François Bastardot; Roland von Känel; Fred Paccaud; Jennifer Glaus; Martin Preisig; Gérard Waeber; Peter Vollenweider
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.